Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
25 hedge funds and large institutions have $15M invested in Regulus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 1 reducing their positions, and 2 closing their positions.
1,100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 1
119% more capital invested
Capital invested by funds: $6.82M → $15M (+$8.14M)
4.46% more ownership
Funds ownership: 47.77% → 52.23% (+4.5%)
4% less funds holding
Funds holding: 26 → 25 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.29M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$740K |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$667K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$54.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$50.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$15.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.33K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$655 |
RGLS Hedge Fund Activity: Q2 2023 in Review
25 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2023, worth a combined $15M — up 119% from $6.82M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of RGLS and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 12 added.
The largest buyer was Federated Hermes, adding an estimated $1.29M. The largest seller was Jane Street, exiting entirely with an estimated $15.4K sold.
- 25 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $15M of Regulus Therapeutics stock for Q2 2023, up 119% quarter-over-quarter.
- 1 fund opened new Regulus Therapeutics positions in Q2 2023 and 2 closed out, a net change of -1 holder.
- The largest Regulus Therapeutics buyer in Q2 2023 was Federated Hermes, an estimated $1.29M added.
- The largest Regulus Therapeutics seller in Q2 2023 was Jane Street, an estimated $15.4K sold.
Based on aggregated 13F filings for Q2 2023.